Skip to content

MucPreDex: Radiation-induced MUCositis PREvention using DEXpanthenol mouth rinse

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-510522-32-00
Acronym
STR-202301
Enrollment
126
Registered
2024-10-30
Start date
2025-08-29
Completion date
Unknown
Last updated
2025-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

radiation-induced oral mucositis

Brief summary

Grading of oral mucositis according to NCI CTCAE v5.0

Detailed description

Grading of oral mucositis according to NCI CTCAE v5.0, Number of cases with oral mucositis, Gustometry score (including the taste qualities, sour, bitter, and salty), the results of the rhinomanometry examination of nasal pressure (resistance coefficient between the nostril and the nasopharynx), the results of the rhinomanometry examination of airflow during breathing per side, assessed by the trial personnel: Grading of Fatigue, oral pain, dysphagia, and weight loss according to NCI CTCAE v5.0, from the subject’s perspective: EORTC QLQ – C30 questionnaire: item scales (Dyspnoea, Insomnia, Appetite loss, Constipation, Diarrhoea, Financial difficulties), functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning), and symptom scales (Fatigue, Nausea and vomiting, pain), from the subject’s perspective: EORTC QLQ–H&N43 questionnaire: item scales (Social contact, Swelling in the neck, Coughing, Neurological problems, Problems opening mouth, Weight loss, Problems with wound healing) and multi-item scales (Social eating, Body image, Pain in the mouth, Problems with senses, Fear of progression/Anxiety, Skin problems, Speech, Swallowing, Problems with teeth, Dry mouth and sticky saliva, Problems with shoulder), a) radiotherapy: Proportion of patients, who prematurely terminate their radiation therapy or have delays in therapy fractions due to adverse effects associated with radiotherapy, a) radiotherapy: Percentage compliance of subjects with planned radiotherapy, b) IMP treatment: Number of unopened IMP bottles returned and opened IMP bottles returned with remaining content, Frequency and intensity of adverse reactions of the IMP, Frequency and intensity of collateral symptoms related to radiotherapy (expected radiation adverse events per NCI CTCAE v5.0)

Interventions

DRUGAqua conservata
DRUGBepanthen® LÖSUNG 50 mg/ml Lösung

Sponsors

Rheinische Friedrich-Wilhelms-Universitaet Bonn
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Grading of oral mucositis according to NCI CTCAE v5.0

Secondary

MeasureTime frame
Grading of oral mucositis according to NCI CTCAE v5.0, Number of cases with oral mucositis, Gustometry score (including the taste qualities, sour, bitter, and salty), the results of the rhinomanometry examination of nasal pressure (resistance coefficient between the nostril and the nasopharynx), the results of the rhinomanometry examination of airflow during breathing per side, assessed by the trial personnel: Grading of Fatigue, oral pain, dysphagia, and weight loss according to NCI CTCAE v5.0, from the subject’s perspective: EORTC QLQ – C30 questionnaire: item scales (Dyspnoea, Insomnia, Appetite loss, Constipation, Diarrhoea, Financial difficulties), functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning), and symptom scales (Fatigue, Nausea and vomiting, pain), from the subject’s perspective: EORTC QLQ–H&N43 questionnaire: item scales (Social contact, Swelling in the neck, Coughing, Neurological problems, Problems

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026